Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (MTNB)
Filing Type: Form 8-K (Current Report)
Report Date: November 8, 2023
Reporting Period: Quarter ended September 30, 2023
This filing serves as a notification that the Company issued a press release announcing its financial results for the third quarter of 2023. The full text of the press release is included as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text acts as a cover document and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
No specific material changes or comparative financial data versus prior periods are detailed in the body of this filing. The document solely references the announcement of results for the quarter ended September 30, 2023.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release by the Company but does not summarize management's commentary, guidance, or outlook within the text provided.
Risks and Contingencies: No specific risks or contingencies are described in this filing text.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2023 revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the Company provided updated full-year 2023 guidance in the referenced press release.